Predispositional Testing Segment Drives Predictive Genetic Testing Market Growth Based on Type
According to our new research study on “Predictive Genetic Testing Market Forecast to 2031 – Global Analysis – by Type, Disease, and End User,” the market is expected to grow from US$1,421.39 million in 2024 to US$4,205.43 million by 2031, registering a CAGR of 17.1% during 2025–2031. Major factors driving the predictive genetic testing market growth include the rising prevalence of genetic diseases, increasing awareness and acceptance of personalized medicines, and surging preference for direct-to-consumer (DTC) genetic testing.
Predictive genetic testing pinpoints the inherited risk factors of an individual for specific diseases long before the appearance of any symptoms. Such tests, which examine genetic differences associated with cancer, cardiovascular diseases, and neurological disorders, aid in early detection, prevention, and personalized healthcare planning. Improvements in next-generation sequencing, bioinformatics, and AI-driven variant interpretation have made the tests more accurate and less costly. An increasing number of people are becoming advocates for preventive healthcare, lifestyle management, and precision medicine, which is the main reason for the widespread use of such testing. Predictive genetic testing is the choice of healthcare providers, diagnostic laboratories, and wellness services that want to guide their patients in understanding health risks, making decisions, and improving outcomes in the long run.
Predictive Genetic Testing Market, by Region, 2024 (%)
Predictive Genetic Testing Market Demand, Trends & Forecast 2031
Download Free Sample
Predictive Genetic Testing Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Predispositional Testing and Presymptomatic Testing), Disease (Cancer, Cardiovascular Diseases, Metabolic Diseases, and Other Diseases), End User (Hospital-Based Laboratories, Diagnostic Laboratories, and Other End Users), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Predictive Genetic Testing Market Demand, Trends & Forecast 2031
Download Free SamplePredictive Genetic Testing Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Predispositional Testing and Presymptomatic Testing), Disease (Cancer, Cardiovascular Diseases, Metabolic Diseases, and Other Diseases), End User (Hospital-Based Laboratories, Diagnostic Laboratories, and Other End Users), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Source: The Insight Partners Analysis
Predictive Genetic Testing Market Analysis Based on Segmental Evaluation:
By type, the market is bifurcated into predispositional testing and presymptomatic testing. Predispositional testing accounted for the largest predictive genetic testing market share in 2024. The growing focus on early disease risk identification, the advances in genetic sequencing, and the rising interest in preventive healthcare give consumers the freedom to plan their lifestyle in a personalized way and to make their medical decisions proactively.
The scope of the Predictive Genetic Testing market report encompasses an assessment of the market's performance in North America, Europe, Asia Pacific, South America, Central America, and MEA. In terms of revenue, North America dominated the predictive genetic testing market in 2024.
The predictive genetic testing market in North America is segmented into the US, Canada, and Mexico. North America accounted for nearly half of the total global share in 2024. Predictive genetic testing in North America remains a well-established practice and a global trendsetter. Significant consumer awareness, a well-developed healthcare system, and substantial research funding have been the main factors behind the widespread adoption of this technology. Large companies, in the US and Canada, have become the main attraction of the market through direct-to-consumer (DTC) testing and clinical applications, such as 23andMe, Myriad Genetics, and Invitae. There are numerous R&D investments, with venture capital being invested in genomics startups, while major technology companies involved in genetic data research are playing a significant role. With such a well-developed ecosystem in place, North America is likely to remain the leader in predictive genetic testing while capitalizing on the synergy between clinical medicine and consumer wellness.
In the US, predictive genetic testing is deeply integrated into both consumer wellness and clinical healthcare. The nation leads globally, driven by large genomics companies such as 23andMe, Myriad Genetics, and Invitae. A strong venture‑capital ecosystem backing R&D. The Genetic Information Non-discrimination Act (GINA) helps protect individuals from discrimination based on genetic risk in health insurance and employment, encouraging use of predictive testing. However, consumer genetic testing remains under scrutiny. In 2025, over two dozen US states filed a lawsuit against 23andMe over its plan to sell customer genetic data during its bankruptcy proceedings, highlighting concerns about data privacy. Meanwhile, the adoption of predictive tests in clinical settings continues to rise, particularly for cancer risk panels and multigene tests, supported by FDA-authorized offerings and growing physician acceptance. Despite challenges around data privacy and business model sustainability, the US remains the most influential market for predictive genetic testing.
Illumina, Inc, 23andMe Holding Co, F. Hoffmann-La Roche Ltd, Ambry Genetics Corp, Myriad Genetics Inc, Exact Sciences Corp, Laboratory Corp of America Holdings, Quest Diagnostics Inc, Thermo Fisher Scientific Inc., NeoGenomics Inc are among the leading companies profiled in the predictive genetic testing market report.
In terms of disease, the predictive genetic testing market is categorized into cancer, cardiovascular diseases, metabolic diseases, and other diseases. The cancer segment held the largest predictive genetic testing market share in 2024. Based on end user, the predictive genetic testing market is segmented into hospital-based laboratories, diagnostic laboratories, and other end users. Geographically, the market is categorized into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East and Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East and Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com